U.S. Immunoglobulin Market Size, Share & COVID-19 Impact Analysis, By Route of Administration (Intravenous, and Subcutaneous), By Indication (Primary Immunodeficiency, Secondary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy, Syndrome, Immune Thrombocytopenic Purpura, Multifocal Motor Neuropathy, and Others), By Form (Liquid and Lyophilized), By End-user (Hospitals, Clinics, and Homecare), and Country Forecast, 2023-2030

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI108226

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2030
Base Year	2022
Estimated Year	2023
Forecast Period	2023-2030
Historical Period	2019-2021
Growth Rate	CAGR of 8.7% from 2023 to 2030
Unit	Value (USD Billion)
Segmentation	By Route of Administration Intravenous Subcutaneous
	By Indication Primary Immunodeficiency (PI) Secondary Immunodeficiency (SI) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Guillain Barré Syndrome Immune Thrombocytopenic Purpura (ITP) Multifocal Motor Neuropathy (MMN) Others
	By Form Liquid Lyophilized
	By End User Hospitals Clinics Homecare